CA3064017C - Cycles 6-5 fusionnes utilises en tant qu'inhibiteurs de c5a - Google Patents

Cycles 6-5 fusionnes utilises en tant qu'inhibiteurs de c5a

Info

Publication number
CA3064017C
CA3064017C CA3064017A CA3064017A CA3064017C CA 3064017 C CA3064017 C CA 3064017C CA 3064017 A CA3064017 A CA 3064017A CA 3064017 A CA3064017 A CA 3064017A CA 3064017 C CA3064017 C CA 3064017C
Authority
CA
Canada
Prior art keywords
mmol
alkyl
group
compound
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3064017A
Other languages
English (en)
Other versions
CA3064017A1 (fr
Inventor
Pingchen Fan
Christopher W. Lange
Rebecca M. LUI
Viengkham Malathong
Venkat Reddy Mali
Sreenivas Punna
Rajinder Singh
Hiroko Tanaka
Yibin Zeng
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Priority claimed from PCT/US2018/034905 external-priority patent/WO2018222598A1/fr
Publication of CA3064017A1 publication Critical patent/CA3064017A1/fr
Application granted granted Critical
Publication of CA3064017C publication Critical patent/CA3064017C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne, entre autres, des composés de formule (I) ou des sels pharmaceutiquement acceptables de ceux-ci qui sont des modulateurs du récepteur C5a. L'invention concerne également des compositions pharmaceutiques et des procédés d'utilisation comprenant le traitement de maladies ou de troubles impliquant une activation pathologique à partir d'applications de C5a et d'applications non-pharmaceutiques.
CA3064017A 2017-05-31 2018-05-29 Cycles 6-5 fusionnes utilises en tant qu'inhibiteurs de c5a Active CA3064017C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762513010P 2017-05-31 2017-05-31
US62/513,010 2017-05-31
PCT/US2018/034905 WO2018222598A1 (fr) 2017-05-31 2018-05-29 Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a

Publications (2)

Publication Number Publication Date
CA3064017A1 CA3064017A1 (fr) 2018-12-06
CA3064017C true CA3064017C (fr) 2025-09-16

Family

ID=

Similar Documents

Publication Publication Date Title
US11773091B2 (en) 6-5 fused rings as C5a inhibitors
EP3630774B1 (fr) Cycles 5-5 fusionnés utilisés en tant qu'inhibiteurs de c5a
CA2893597A1 (fr) Lactames de diazole
CA2883353C (fr) Antagonistes des recepteurs de chimiokine
CA3064017C (fr) Cycles 6-5 fusionnes utilises en tant qu'inhibiteurs de c5a
RU2780338C2 (ru) 6-5 КОНДЕНСИРОВАННЫЕ КОЛЬЦА КАК ИНГИБИТОРЫ С5а
HK40026727B (en) 6-5 fused rings as c5a inhibitors
HK40026727A (en) 6-5 fused rings as c5a inhibitors
BR122024024491B1 (pt) Método in vitro para inibir a quimiotaxia celular mediada por c5a
BR112019025049B1 (pt) Compostos com anéis 6- 5 fundidos e composição farmacêutica que os compreende
BR122024024491A2 (pt) Compostos com anéis 6- 5 fundidos, composição farmacêutica, seus usos como inibidores de c5a e método in vitro para inibir a quimiotaxia celular mediada por c5a
HK40026719A (en) 5-5 fused rings as c5a inhibitors
HK40026719B (en) 5-5 fused rings as c5a inhibitors